<DOC>
	<DOCNO>NCT01037023</DOCNO>
	<brief_summary>Non-interventional , open-label , single group , multicentric post-marketing surveillance monitor safety effectiveness Topotecan administer Korean patient accord prescribe information</brief_summary>
	<brief_title>Regulatory Hycamtin ( Oral ) PMS</brief_title>
	<detailed_description>Non-interventional , open-label , single group , multicentric post-marketing surveillance monitor safety effectiveness Topotecan administer Korean patient accord prescribe information Topotecan administer describe prescribe information physician 's decision .</detailed_description>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>All subject must satisfy follow criterion . Subject indication prescribe information oral Hycamtin . Subject treat oral Hycamtin accord judgement investigator . All subject must satisfy follow criterion . â€¢ Subject contraindication prescribe information oral Hycamtin . As consider characteristic observational post marketing surveillance , exclusion criterion strict . All investigator prescribe oral Hycamtin accord prescribe information approve Korea .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>PMS ( post-marketing surveillance )</keyword>
	<keyword>Topotecan</keyword>
</DOC>